CA2357765A1 - Acide niflumique liposomique - un nouveau medicament anti-inflammatoire transdermique - Google Patents

Acide niflumique liposomique - un nouveau medicament anti-inflammatoire transdermique Download PDF

Info

Publication number
CA2357765A1
CA2357765A1 CA002357765A CA2357765A CA2357765A1 CA 2357765 A1 CA2357765 A1 CA 2357765A1 CA 002357765 A CA002357765 A CA 002357765A CA 2357765 A CA2357765 A CA 2357765A CA 2357765 A1 CA2357765 A1 CA 2357765A1
Authority
CA
Canada
Prior art keywords
niflumic acid
liposomes
encapsulation
medicine
ear
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002357765A
Other languages
English (en)
Inventor
Helen Kammenou
Michalis Rallis
Georgios Tsamouris
Aristidis Georgopoulos
Georgios Papaioannou
Georgios Giannisis
Sofia Hatziantoniou
Konstantinos Demetzos
Georgios Nounesis
Christina Savva-Dimopoulou
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
PN Gerolymatos SA
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2357765A1 publication Critical patent/CA2357765A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1277—Preparation processes; Proliposomes
    • A61K9/1278—Post-loading, e.g. by ion or pH gradient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/465—Nicotine; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cosmetics (AREA)

Abstract

La présente invention concerne l'encapsulation du médicament acide niflumique dans des liposomes dans le but de créer une nouvelle formulation anti-inflammatoire non stéroïdienne et transdermique. L'acide niflumique est ses dérivés esters ont été encapsulés dans les liposomes avec différentes formulations de lipides pour augmenter l'efficacité du composé actif. La suspension de liposomes, avec ou sans le produit encapsulé, a été formulée sous forme de crème. Par ailleurs, une étude de stabilité de la formulation finale a été effectuée.
CA002357765A 1998-12-24 1999-12-22 Acide niflumique liposomique - un nouveau medicament anti-inflammatoire transdermique Abandoned CA2357765A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GR98100469 1998-12-24
GR980100469 1998-12-24
PCT/GR1999/000048 WO2000038681A1 (fr) 1998-12-24 1999-12-22 Acide niflumique liposomique - un nouveau medicament anti-inflammatoire transdermique

Publications (1)

Publication Number Publication Date
CA2357765A1 true CA2357765A1 (fr) 2000-07-06

Family

ID=10943556

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002357765A Abandoned CA2357765A1 (fr) 1998-12-24 1999-12-22 Acide niflumique liposomique - un nouveau medicament anti-inflammatoire transdermique

Country Status (17)

Country Link
EP (1) EP1140089A1 (fr)
JP (1) JP2002533394A (fr)
KR (1) KR20010089889A (fr)
CN (1) CN1331592A (fr)
AU (1) AU1673400A (fr)
BR (1) BR9917006A (fr)
CA (1) CA2357765A1 (fr)
CZ (1) CZ20012240A3 (fr)
GR (1) GR1003359B (fr)
HU (1) HUP0104853A3 (fr)
IL (1) IL143499A0 (fr)
IS (1) IS5964A (fr)
MX (1) MXPA01006462A (fr)
NO (1) NO20013015L (fr)
PL (1) PL349344A1 (fr)
SK (1) SK7962001A3 (fr)
WO (1) WO2000038681A1 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003298738A1 (en) * 2002-11-26 2004-06-18 Su-Ming Chiang Liposomal formulations
KR20060015534A (ko) * 2003-04-25 2006-02-17 더 펜 스테이트 리서치 파운데이션 성장 억제, 지질 유래된 생활성 화합물의 전신 전달을 위한방법 및 시스템
US20050255154A1 (en) 2004-05-11 2005-11-17 Lena Pereswetoff-Morath Method and composition for treating rhinitis
JP4791082B2 (ja) * 2005-05-30 2011-10-12 株式会社クラレ リポソームおよびそれを含む皮膚外用剤
JP4931369B2 (ja) * 2005-05-31 2012-05-16 ポーラ化成工業株式会社 リポソームおよびそれを含む処置用の組成物
EP1888033B1 (fr) 2005-06-09 2014-02-19 Meda AB Methode et composition de traitement de troubles inflammatoires
US20120028335A1 (en) 2010-07-28 2012-02-02 Life Technologies Corporation Anti-viral azide-containing compounds
US20130209550A1 (en) 2010-07-28 2013-08-15 Life Technologies Corporation Anti-Viral Azide Containing Compounds
US9890361B2 (en) 2012-01-26 2018-02-13 Life Technologies Corporation Methods for increasing the infectivity of viruses utilizing alkyne-modified fatty acids

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4528193A (en) * 1978-12-27 1985-07-09 A. Natterman & Cie. Gmbh Inflammation-preventing pharmaceutical composition of oral administration
EP0225162B1 (fr) * 1985-11-27 1992-01-22 Ethicon, Inc. Inhibition de la formation de l'adhérence postchirurgicale par l'administration topique d'un médicament anti-inflammatoire non stéroide
ES2036593T3 (es) * 1986-06-12 1993-06-01 The Liposome Company, Inc. Composiciones que utilizan medicamentos antiinflamatorios no esteroidales encapsulados en liposomas.
EP0825852B1 (fr) * 1995-04-18 2004-07-07 Yissum Research Development Company Of The Hebrew University Of Jerusalem Procede de chargement de medicaments dans des liposomes et composition

Also Published As

Publication number Publication date
JP2002533394A (ja) 2002-10-08
EP1140089A1 (fr) 2001-10-10
MXPA01006462A (es) 2002-06-04
GR1003359B (el) 2000-04-10
AU1673400A (en) 2000-07-31
CN1331592A (zh) 2002-01-16
NO20013015D0 (no) 2001-06-18
SK7962001A3 (en) 2002-02-05
KR20010089889A (ko) 2001-10-12
HUP0104853A3 (en) 2003-05-28
HUP0104853A2 (hu) 2002-05-29
IL143499A0 (en) 2002-04-21
PL349344A1 (en) 2002-07-15
NO20013015L (no) 2001-06-18
CZ20012240A3 (cs) 2001-11-14
WO2000038681A1 (fr) 2000-07-06
IS5964A (is) 2001-06-08
BR9917006A (pt) 2001-10-30

Similar Documents

Publication Publication Date Title
US5077057A (en) Preparation of liposome and lipid complex compositions
KR0140088B1 (ko) 하나 이상의 활성물질이 충전된 중합체 또는 지방물질이 미세구형체를 함유하는 미용 또는 조성물
EP0088046B1 (fr) Lipides en phase aqueuse
US4897269A (en) Administration of drugs with multiphase liposomal delivery system
US4761288A (en) Multiphase liposomal drug delivery system
DE69535297T2 (de) Zubereitung multivesikulärer liposomen zur gesteuerten freisetzung von wirkstoffen
US5277914A (en) Preparation of liposome and lipid complex compositions
JP2020521810A (ja) ビファシックス（ｂｉｐｈａｓｉｘ）・カンナビノイド送達
EP0177223B1 (fr) Composition pharmaceutique à multiphases
DE4447287C1 (de) Präparat zum Wirkstofftransport durch Barrieren
US8778367B2 (en) Glycerosomes and use thereof in pharmaceutical and cosmetic preparations for topical applications
JPH08208457A (ja) ステロールリポソームの調製方法
DE3852961T2 (de) Arzneistoff-Lipid-Systeme mit geringer Toxizität.
HU208070B (en) Process for producing lipid suspension
EP1140089A1 (fr) Acide niflumique liposomique - un nouveau medicament anti-inflammatoire transdermique
JPH04503676A (ja) 医薬品
DK3145490T3 (en) LIPOSOMES CONTAINING DI-HOMO-GAMMA LINOLIC ACID (DGLA), FORMULATIONS CONTAINING THEM AND APPLICATION THEREOF
Sulkowski et al. Effect of temperature on liposome structures studied using EPR spectroscopy
JP2004538295A (ja) 少なくとも１種のｄｈｅａ化合物を導入した脂質ラメラ小胞に基づく組成物
CA3002387A1 (fr) Formulations d'isotretinoine et utilisations connexes
SK5382002A3 (en) Liposome formulation of 6,9-bis-[(2-aminoethyl)-amino]benzo[g] isoquinoline-5,10-dione dimaleate
Auner et al. Influence of 6‐ketocholestanol on skin permeation of 5‐aminolevulinic acid and evaluation of chemical stability
RU2740553C2 (ru) Способ получения липосомальной формы бетулина, обладающей гепатопротекторной активностью
JPH04503677A (ja) 薬剤学的製剤
Dongare et al. Available through Online Review Article www. ijptonline. com

Legal Events

Date Code Title Description
FZDE Discontinued